Regeneron and Alnylam link up to pursue RNAi therapeutics in ophthalmic and central nervous system indications in a deal that could be worth up to $1 billion
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.